(NASDAQ: IRWD) Ironwood Pharmaceuticals's forecast annual revenue growth rate of 0.26% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 136.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.78%.
Ironwood Pharmaceuticals's revenue in 2025 is $338,987,000.On average, 6 Wall Street analysts forecast IRWD's revenue for 2026 to be $52,999,076,406, with the lowest IRWD revenue forecast at $49,454,308,688, and the highest IRWD revenue forecast at $57,051,401,503. On average, 5 Wall Street analysts forecast IRWD's revenue for 2027 to be $55,702,795,519, with the lowest IRWD revenue forecast at $52,195,443,890, and the highest IRWD revenue forecast at $58,759,527,296.
In 2028, IRWD is forecast to generate $58,574,073,639 in revenue, with the lowest revenue forecast at $56,277,051,143 and the highest revenue forecast at $60,296,840,511.